Health and Healthcare
Short Sellers Back Off of Major Biotechs
Published:
Last Updated:
The short interest data are out for the February 29 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or break them. A single failed clinical trial can mean disaster for a stock. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
The February 29 short interest data have been compared with the previous report, and short interest decreased across the board in these selected stocks for this settlement date.
Amgen Inc. (NASDAQ: AMGN) saw its short interest fall to 9.97 million shares from the previous level of 10.63 million. Shares closed most recently at $140.90, in a 52-week trading range of $130.09 to $181.81.
Biogen Inc. (NASDAQ: BIIB) had its short interest decrease to 2.73 million from the previous level of 3.37 million. Shares closed Wednesday at $255.66, within a 52-week range of $242.07 to $480.18.
Celgene Corp. (NASDAQ: CELG) short interest for this settlement date increased to 13.34 million shares from the previous 11.74 million. Shares of Celgene closed most recently at $101.04, in a 52-week range of $92.98 to $140.72.
24/7 Wall St.Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
